Formerly known as COL-3, Incyclinide will start a new Phase 2, double-blinded, placebo-controlled trial to find the best treatment dose. This trial will evaluate 300 patients for moderate to severe acne. A recent Phase 2 Clinical Trial showed some promise for inflammatory lesions in rosacea.
Incyclinide is a chemically modified tetracycline, modified to retain non-antibiotic properties that may make them effective in treating diseases involving inflammation and/or destruction of the body’s connective tissues.
Related Articles:
- Incyclinide (CollaGenex) gets NIH Funding
- COL-3 new tetracycline derivative being studied
- low dose doxycycline hyclate (SDD)
- Subantimicrobial Dose Doxycycline for Acne and Rosacea
- Periostat (doxycycline) goes generic, get ready for Oracea
- incyclinide targets conditions other than rosacea
- how do tetracyclines help rosacea ?
- incyclinide fails for rosacea, acne still possible
